欧洲单克隆抗体市场预测至 2028 年 - COVID-19 影响和区域分析（按来源（人、人源化、嵌合和鼠）、生产方法（体外和体内）、适应症（癌症、自身免疫性疾病、传染病） 、炎症性疾病、微生物疾病等）、应用（治疗应用、诊断应用和研究应用）、最终用户（医院、研究所等）
No. of Pages: 172 | Report Code: TIPRE00027983 | Category: Life Sciences
No. of Pages: 172 | Report Code: TIPRE00027983 | Category: Life Sciences
今天，FDA 批准用于紧急用途的 mAB 治疗 COVID-19 患者，结果证明它是成功的通过缩短住院时间，将严重疾病、住院和死亡的几率减少近 70%。除此之外，用于治疗 COVID-19 的 mAB 产品的覆盖范围是大流行爆发期间该市场增长的另一个因素。此外，国家健康与护理卓越研究所 (NICE) 更新了管理 COVID-19 指南和单克隆抗体建议。据记录，2021 年 10 月，新建议建议联合使用“casirivimab”和“imdevimab”来治疗 12 岁及以上住院的 COVID-19 患者。此外，这两种产品都获得了用于预防和治疗急性 COVID-19 感染的许可。
欧洲市场因新冠肺炎疫情受到严重打击。该地区的 COVID-19 病例呈指数级增长。许多国家现在每天发现的患者数量比今年早些时候第一波疫情期间还要多。根据欧洲疾病预防和控制中心 (ECDC) 的数据，英国、西班牙、意大利和爱尔兰正在重新实施封锁。由于第二波 COVID-19 危机，许多国家的政府正在努力提高检测能力。欧洲地区国家因 COVID-19 大流行而受到严重影响。例如，意大利、西班牙和法国等国家的阳性病例数最多，死亡人数最多。冠状病毒发病率的上升导致该地区医疗保健系统的压力增加，增加了医疗保健系统中诊断测试的需求，支持了该地区该行业的扩张。此外，2021年12月，辉瑞和BioNTech宣布，两家公司将修改临床安全性研究，同时评估辉瑞-BioNTech COVID-19疫苗在6个月至5岁以下儿童中的安全性、耐受性和免疫原性。
借助新功能和技术，供应商可以吸引新客户并扩大其在新兴市场的足迹。这一因素可能会推动单克隆抗体市场。欧洲单克隆抗体市场预计在预测期内将以良好的复合年增长率增长。
Strategic insights for Europe Monoclonal Antibodies involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 29,254.3 Million |
| Market Size by 2028 | US$ 61,019.8 Million |
| Global CAGR (2021 - 2028) | 11.1% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By 来源
|
| Regions and Countries Covered | 欧洲
|
| Market leaders and key company profiles |
The regional scope of Europe Monoclonal Antibodies refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Europe Monoclonal Antibodies Market is valued at US$ 29,254.3 Million in 2021, it is projected to reach US$ 61,019.8 Million by 2028.
As per our report Europe Monoclonal Antibodies Market, the market size is valued at US$ 29,254.3 Million in 2021, projecting it to reach US$ 61,019.8 Million by 2028. This translates to a CAGR of approximately 11.1% during the forecast period.
The Europe Monoclonal Antibodies Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Monoclonal Antibodies Market report:
The Europe Monoclonal Antibodies Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Monoclonal Antibodies Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Monoclonal Antibodies Market value chain can benefit from the information contained in a comprehensive market report.
E 1803, Panchshil Towers, Vagholi, Haveli, Pune- 412207, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Monoclonal Antibodies Market
